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Abstract 
A detailed comparative study on chemical and bioactive properties of wild and 
cultivated Ganoderma lucidum from Serbia (GS) and China (GCN) was performed. 
This species was chosen because of their worldwide use as medicinal mushroom. 
Higher amounts of sugars were found in GS, while higher amounts of organic acids 
were recorded in GCN. Unsaturated fatty acids predominated over saturated fatty acids. 
GCN revealed higher antioxidant activity, while GS exhibited inhibitory potential 
against human breast and cervical carcinoma cell lines. No cytotoxicity in non-tumour 
liver primary cell culture was observed for the different samples. Both samples 
possessed antibacterial and antifungal activities, in some cases even better than the 
standard antimicrobial drugs. This is the first study reporting a comparative of chemical 
compounds and bioactivity of G. lucidum samples from different origins.  
 
Keywords: Ganoderma lucidum; Chemical composition; Antioxidant activity; 
Cytotoxicity; Antimicrobial activity.  
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Introduction 
Ganoderma lucidum (Curtis) P. Karst is a mushroom that has been widely used as a 
tonic for promoting longevity in Traditional Chinese Medicine and also in other Asian 
countries as healthy food, for more than 2000 years (Paterson, 2006). This medicinal 
mushroom is commonly used in the treatment of bronchitis, asthma, 
hypercholesterolemia, hepatopathy, hypertension, arthritis, neurasthenia, hypertension, 
immunological diseases, gastric ulcers, chronic hepatitis, nephritis, and insomnia 
(Zhong and Tang, 2004; Liu and Zhang, 2005; Xie et al. 2006; Huang and Ning, 2010; 
Teng et al. 2011). Currently, G. lucidum is among the most sought medicinal 
mushrooms in the world market. Various products are being prepared from its cultivated 
fruiting bodies and have been commercialized as dietary supplements worldwide (Lai et 
al. 2004). 
The beneficial health effects of Ganoderma species are attributed to different bioactive 
molecules such as phenolics, polysaccharides, triterpenes, sterols, lectins and proteins 
(Ferreira et al. 2010; Heleno et al. 2012).  Some studies with wild mushrooms report the 
growth habitat as a very important factor influencing the profile and amounts of 
biomolecules with active principles (Heleno et al. 2013).  According to Karthikeyan et 
al. (2007) the differences in the chemical composition of G. lucidum, were attributed to 
different sites of collection. 
It was previously demonstrated that free radical scavenging properties, reducing power 
and lipid peroxidation inhibition of G. lucidum was correlated with phenolic 
compounds, but also with polysaccharides (Heleno et al. 2012; Kozarski et al. 2012; 
Wang et al. 2013) and peptides (Girjal et al. 2012). The contemporary view of cancer is 
that malignant tumours arise and progress through the accumulation of successive 
mutations, which involve activation of proto-oncogenes and inactivation of tumour 
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suppressor genes, leading to uncontrolled proliferation of the progeny cells (Ajith and 
Janardhanan, 2011). There are clinical evidences of complete regression of gastric large 
B-cell lymphoma with G. lucidum spore powder treatment (60 capsules daily for 5 days, 
which is 3 times the dose recommended by the manufacturer) (Cheuk et al. 2007). Some 
recent studies described ethanol and polysaccharide extracts of G. lucidum, as in vitro 
inhibitors of various cancer cell lines: melanoma, gastric carcinoma and inflammatory 
breast cancer (Martinez-Montemayor et al. 2011; Jang et al. 2011; Zheng et al. 2012; 
Sun et al. 2012). Nevertheless, the mechanism of antitumour action of G. lucidum 
requires more detailed study. Although huge diversity of antibacterial drugs is currently 
described, bacterial resistance to first choice antibiotics has rapidly and drastically 
grown. The discovery and development of new antibiotics is a central strategy in 
combating bacterial drug resistance (Moir et al. 2012). Antimicrobial activity of 
different G. lucidum extracts (acetone and methanol) was also reported, indicating 
differences between the kind of extracts and the sample used (Alves et al. 2012). 
In the present work, G. lucidum samples from Serbia (GS) and China (GCN) were 
submitted to a detailed comparative study regarding: nutritional value, hydrophilic 
compounds (free sugars, organic acids and phenolic compounds), lipophilic compounds 
(fatty acids, tocopherols and ergosterol), bioactive properties (antioxidant, cytotoxic, 
and antimicrobial activities) and hepatotoxicity.  
 
 
Materials and methods 
Samples 
The material of wild Ganoderma lucidum (Curtis) P. Karst was collected from 
Bojčinska forest, Belgrade, Serbia, in autumn 2012, and authenticated by Dr. Jasmina 
Glamočlija (Institute for Biological Research). A voucher specimen has been deposited 
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at the Fungal Collection Unit of the Mycological Laboratory, Department for Plant 
Physiology, Institute for Biological Research “Siniša Stanković”, Belgrade, Serbia, 
under number Gl-009-2012. A batch of cultivated G. lucidum was obtained from China, 
identified by dr LJLD van Griensven and stored dry for later use.  
Both specimens were lyophilised (LH Leybold, Lyovac GT2, Frenkendorf, 
Switzerland), reduced to a fine dried powder (20 mesh), mixed to obtain a homogeneous 
sample and kept at -20 ºC until further analysis. 
 
Standards and Reagents 
Acetonitrile 99.9%, n-hexane 95% and ethyl acetate 99.8% were of HPLC grade from 
Fisher Scientific (Lisbon, Portugal). The fatty acids methyl ester (FAME) reference 
standard mixture 37 (standard 47885-U) was purchased from Sigma (St. Louis, MO, 
USA), as also were other individual fatty acid isomers, trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid), ergosterol, tocopherol and sugar standards. 
Phenolic compound standards were from Extrasynthese (Genay, France). Racemic 
tocol, 50 mg/mL, was purchased from Matreya (PA, USA). 2,2-Diphenyl-1- 
picrylhydrazyl (DPPH) was obtained from Alfa Aesar (Ward Hill, MA, USA). Fetal 
bovine serum (FBS), L-glutamine, hank’s balanced salt solution (HBSS), trypsin-EDTA 
(ethylenediaminetetraacetic acid), penicillin/streptomycin solution (100 U/mL and 100 
mg/mL, respectively), RPMI-1640 and DMEM media were from Hyclone (Logan, 
USA). Acetic acid, ellipticine, sulforhodamine B (SRB), trypan blue, trichloroacetic 
acid (TCA) and Tris were from Sigma Chemical Co. (Saint Louis, USA). Mueller–
Hinton agar (MH) and malt agar (MA) were obtained from the Institute of Immunology 
and Virology, Torlak (Belgrade, Serbia). Dimethylsulfoxide (DMSO), (Merck KGaA, 
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Germany) was used as a solvent. Water was treated in a Milli-Q water purification 
system (TGI Pure Water Systems, USA).  
 
Chemical composition  
Nutritional value. The samples were analysed for chemical composition (moisture, 
proteins, fat, carbohydrates and ash) using the AOAC procedures (AOAC, 1995). The 
crude protein content (N×4.38) of the samples was estimated by the macro-Kjeldahl 
method; the crude fat was determined by extracting a known weight of powdered 
sample with petroleum ether, using a Soxhlet apparatus; the ash content was determined 
by incineration at 600±15 ºC. Total carbohydrates were calculated by difference. Energy 
was calculated according to the following equation: Energy (kcal) = 4 × (g protein + g 
carbohydrate) + 9 × (g fat).  
 
Hydrophilic compounds. Free sugars were determined by high performance liquid 
chromatography coupled to a refraction index detector (HPLC-RI), after extraction and 
analysis procedures previously described by the authors (Heleno et al. 2009) using 
melezitoze as internal standard (IS). The compounds were identified by 
chromatographic comparisons with authentic standards. Quantification was performed 
using the internal standard method and sugar contents were further expressed in g per 
100 g of dry weight (dw). 
Organic acids were determined by ultrafast liquid chromatography coupled to a 
photodiode array detector (UFLC-PAD), following a procedure previously described by 
the authors (Barros et al. 2013). The organic acids found were quantified by comparison 
of the area of their peaks recorded at 215 nm with calibration curves obtained from 
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commercial standards of each compound. The results were expressed in g per 100 g of 
dry weight (dw).  
Phenolic compounds were determined by the same methodology using 280 nm and 370 
nm as preferred wavelengths, according to a procedure previously described by the 
authors (Reis et al. 2012). The phenolic compounds were characterized according to 
their UV and retention times, and comparison with authentic standards. For quantitative 
analysis, calibration curves were prepared from different standard compounds. The 
results were expressed in mg per 100 g of dry weight (dw). 
 
Lipophilic compounds. Fatty acids were determined by gas–liquid chromatography with 
flame ionization detection (GC-FID)/capillary column as described previously by the 
authors (Heleno et al. 2009). The results were expressed in relative percentage of each 
fatty acid. 
Tocopherols were determined following a procedure previously described by the 
authors (Heleno et al. 2010) using HPLC-fluorescence. Quantification was based on the 
fluorescence signal response of each standard, using the IS (tocol) method and by using 
calibration curves obtained from commercial standards of each compound. The results 
were expressed in µg per 100 g of dry weight (dw).  
Ergosterol was determined following a procedure previously described by the authors 
(Barreira et al. 2013) using HPLC-UV and cholecalciferol as internal standard. The 
results were expressed in mg per 100 g of dry weight (dw). 
 
Evaluation of bioactive properties  
Extracts preparation. Each sample (1 g) was extracted by stirring with 25 mL of 
methanol (25 ºC at 150 rpm) for 1 h and subsequently filtered through Whatman No. 4 
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paper. The residue was then extracted with 25 mL of methanol (25 ºC at 150 rpm) for 1 
h. The combined methanolic extracts were evaporated at 40 ºC (rotary evaporator Büchi 
R-210) to dryness. The extracts were redissolved in i) methanol (final concentration 20 
mg/mL) for antioxidant activity evaluation, or ii) water for antitumour cell (final 
concentration 8 mg/mL) and antimicrobial (final concentration 1.5 mg/mL) activity 
evaluation. The final solutions were further diluted to different concentrations to be 
submitted to distinct bioactivity evaluation in vitro assays. The results were expressed in 
i) EC50 values (sample concentration providing 50% of antioxidant activity or 0.5 of 
absorbance in the reducing power assay) for antioxidant activity; ii) GI50 values (sample 
concentration that inhibited 50% of the net cell growth) for cytotoxicity activity in 
human tumour cell lines and non-tumour liver primary cell culture, and MIC (Minimum 
inhibitory concentration); and iii) MBC/MFC (Minimum bactericidal 
concentration/Minimum fungicidal concentration) values for antimicrobial activity. 
Trolox and ellipticine were used as positive controls in antioxidant and cytotoxic 
activity evaluation assays, respectively. Streptomycin and ampicillin were used as 
standards in the antibacterial assay. Bifonazole and ketokonazole were used as standards 
in the antifungal susceptibility test. 
 
Antioxidant activity. DPPH radical-scavenging activity was evaluated by using an 
ELX800 microplate reader (Bio-Tek Instruments, Inc; Winooski, USA), and calculated 
as a percentage of DPPH discolouration using the formula: [(ADPPH-AS)/ADPPH] × 100, 
where AS is the absorbance of the solution containing the sample at 515 nm, and ADPPH 
is the absorbance of the DPPH solution. Reducing power was evaluated by the capacity 
to convert Fe3+ into Fe2+, measuring the absorbance at 690 nm in the microplate reader 
mentioned above. Inhibition of β-carotene bleaching was evaluated though the β-
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carotene/linoleate assay; the neutralization of linoleate free radicals avoids β-carotene 
bleaching, which is measured by the formula: β-carotene absorbance after 2h of 
assay/initial absorbance) × 100. Lipid peroxidation inhibition in porcine (Sus scrofa) 
brain homogenates was evaluated by the decreasing in thiobarbituric acid reactive 
substances (TBARS); the colour intensity of the malondialdehyde-thiobarbituric acid 
(MDA-TBA) was measured by its absorbance at 532 nm; the inhibition ratio (%) was 
calculated using the following formula: [(A - B)/A] × 100%, where A and B were the 
absorbance of the control and the sample solution, respectively (Heleno et al. 2010). 
 
Cytotoxicity in human tumour cell lines and in liver primary cell culture. Five human 
tumour cell lines were used: MCF-7 (breast adenocarcinoma), NCI-H460 (non-small 
cell lung cancer), HCT-15 (colon carcinoma), HeLa (cervical carcinoma) and HepG2 
(hepatocellular carcinoma). Cells were routinely maintained as adherent cell cultures in 
RPMI-1640 medium containing 10% heat-inactivated FBS and 2 mM glutamine (MCF-
7, NCI-H460 and HCT-15) or in DMEM supplemented with 10% FBS, 2 mM 
glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin (HeLa and HepG2 cells), 
at 37 ºC, in a humidified air incubator containing 5% CO2. Each cell line was plated at 
an appropriate density (7.5 × 103 cells/well for MCF-7, NCI-H460 and HCT-15 or 1.0 × 
104 cells/well for HeLa and HepG2) in 96-well plates. Sulforhodamine B assay was 
performed according to a procedure previously described by the authors (Guimarães et 
al. 2013). 
For hepatotoxicity evaluation, a cell culture was prepared from a freshly harvested 
porcine liver obtained from a local slaughter house, according to a procedure 
established by the authors (Guimarães et al. 2013); it was designed as PLP2. Cultivation 
of the cells was continued with direct monitoring every two to three days using a phase 
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contrast microscope. Before confluence was reached, cells were subcultured and plated 
in 96-well plates at a density of 1.0×104 cells/well, and cultivated in DMEM medium 
with 10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. 
 
Test on antimicrobial activity. The following Gram-negative bacteria were used: 
Escherichia coli (ATCC 35210), Pseudomonas aeruginosa (ATCC 27853), Salmonella 
typhimurium (ATCC 13311), Enterobacter cloacae (ATCC 35030) and the following 
Gram-positive bacteria: Staphylococcus aureus (ATCC 6538), Bacillus cereus (clinical 
isolate), Micrococcus flavus (ATCC 10240), and Listeria monocytogenes (NCTC 7973).  
For the antifungal bioassays, microfungi were used: Aspergillus fumigatus (1022), 
Aspergillus ochraceus (ATCC 12066), Aspergillus versicolor (ATCC 11730), 
Aspergillus niger (ATCC 6275), Penicillium funiculosum (ATCC 36839), Penicillium 
ochrochloron (ATCC 9112), Trichoderma viride (IAM 5061), and Penicillium 
aurantiogriseum (food isolate). The organisms were obtained from the Mycological 
Laboratory, Department of Plant Physiology, Institute for Biological Research “Siniša 
Stanković´”, Belgrade, Serbia. 
In order to investigate the antimicrobial activity of the extracts, a modified 
microdilution technique was used (Hanel and Raether, 1988). Bacterial species were 
cultured overnight at 37 °C in Luria broth medium. The fungal spores were washed 
from the surface of agar plates with sterile 0.85% saline containing 0.1% Tween 80 
(v/v). The bacterial cells and fungal spore suspension was adjusted with sterile saline to 
a concentration of approximately 1.0 × 105 in a final volume of 100 µL per well. The 
inocula were stored at 4 °C for further use. Dilutions of the inocula were cultured on 
Müller-Hinton agar for bacteria and solid malt agar for fungi to verify the absence of 
contamination and to check the validity of the inoculum. 
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Minimum inhibitory concentration (MIC) determinations were performed by a serial 
dilution technique using 96-well microtiter plates. The extracts investigated were 
dissolved in 5% DMSO and added in broth medium (bacteria)/broth malt medium 
(fungi) with inocula. The microplates were incubated for 48 h at 37 °C for bacteria or 72 
h at 28 °C for fungi. The following day, 30 µl of 0.2 mg/ml solution of INT (p-
iodonitrotetrazolium violet) was added, and the plates were returned to the incubator for 
at least one-half hour to ensure adequate color reaction. Inhibition of growth was 
indicated by a clear solution or a definite decrease in color reaction. The lowest 
concentrations without visible growth (at the binocular microscope) were defined as 
MICs. The minimum bactericidal concentrations (MBCs) and minimum fungicidal 
concentrations (MFCs) were determined by serial subcultivation of a 2 µL sample into 
microtiter plates containing 100 µL of broth per well and further incubation for 48 h at 
37 °C or 72 h at 28 °C. The lowest concentration with no visible growth was defined as 
MBC/MFC, respectively, indicating 99.5% killing of the original inoculum. 5% DMSO 
was used as a negative control. 
 
Statistical analysis 
For each one of the species three samples were used and all the assays were carried out 
in triplicate. The results are expressed as mean values and standard deviation (SD). The 
results were analyzed using one-way analysis of variance (ANOVA) followed by 
Tukey’s HSD Test with α = 0.05. This treatment was carried out using SPSS v. 18.0 
program.  
 
 
Results and Discussion 
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Chemical and nutrition composition  
The results of the nutritional value, hydrophilic and lipophilic compounds of G. lucidum 
samples from Serbia (GS) and China (GCN) are presented in Tables 1-3. Carbohydrates 
were the most abundant macronutrients, followed by fat or ash, depending on the 
sample. Carbohydrate, fat and protein contents were higher in GS, giving to this sample 
a higher energetic contribution (Table 1). Macronutrients content found in the studied 
samples was comparable to the one reported by Mau et al. (2001) for cultivated G. 
lucidum from China. 
Fructose was the most abundant sugar in GS, while mannitol was the predominant one 
in GCN. Interestingly, five free sugars (fructose, glucose, mannitol, sucrose and 
trehalose) were reported in GS, while only two sugars, namely mannitol and trehalose 
were reported in GCN. Accordingly, high levels of these two sugars have been reported 
in other cultivated mushrooms (Wannet et al. 1999). Total free sugars content was 
notably higher in GS (Table 2). A similar sugars profile (with the same five sugars) and 
total amount (10.29 g/100 g dw) was obtained in a sample of G. lucidum from Portugal 
previously studied by some of us (Heleno et al. 2012).  
Total organic acids content was higher in GCN, where malic acid predominated, 
followed by quinic and oxalic acids. In GS, five organic acids (oxalic, quinic, malic, 
citric and fumaric) were quantified with amounts lower than 0.61 g/100 g dw (Table 2). 
As far as we know, this is the first report on organic acids composition in G. lucidum.  
Protocatechuic and cinnamic acids were found in both samples, while p-hydroxybenzoic 
and p-coumaric acids were only found in GCN and GS, respectively. GCN gave the 
highest amounts of phenolic acids due to the high contribution of protocatechuic acid 
(Table 2). The mentioned amount was higher than the one found in G. lucidum from 
Portugal (1.23 mg/100 g dw; Heleno et al. 2012), but lower than the reported for a 
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sample of G. lucidum from Korea (16.2 mg/100 g dw; Kim et al. 2008). 
Unsaturated fatty acids (UFA) predominated over saturated fatty acids (SFA). 
Monounsaturated fatty acids (MUFA) were dominant in GS, while polyunsaturated fatty 
acids predominated in GCN. The most abundant fatty acids in both GS and GCN were 
linoleic (C18:2n6c), oleic (C18:1n9) and palmitic (C16:0) acids (Table 3). The same 
characteristic was described by other authors for G. lucidum from China (Lv et al. 
2012). α- and δ-Tocopherols were found in GS, while no tocopherols could be recorded 
in GCN; this difference can be due to degradation processes during the growth or 
conservation periods of the latter sample (commercial) since tocopherols are very 
sensitive to light and temperature. Ergosterol content was almost ten times higher in 
GCN than in GS (Table 3). A high variability in ergosterol content among nineteen 
samples from different locations in China (189.1 to 1453.3 µg/g dw), was also reported 
by Lv et al. (2012). Furthermore, Barreira et al. (2013) also reported the same in thirteen 
mushroom species from Portugal.  
 
Bioactive properties 
Antioxidant activity was tested by four different methods that measured free radicals 
scavenging activity, reducing power and lipid peroxidation inhibition (Table 4).   
Both samples revealed antioxidant properties. Nevertheless, GS gave slightly higher 
reducing power, higher DPPH radical scavenging activity and higher β-carotene 
bleaching inhibition (lower EC50 values). GCN gave slightly better results for lipid 
peroxidation inhibition evaluated by TBARS assay.  
The studied samples of G. lucidum revealed higher reducing power (~50% at 0.75 
mg/mL), but lower DPPH scavenging activity (~50% at 0.5 mg/mL) than a sample from 
Taiwan (Mau et al. 2002). Nevertheless, they gave higher DPPH scavenging activity 
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than samples from Korea (~74% at 10 mg/mL; Kim et al. 2008). In general, G. lucidum 
from Portugal, previously studied by some of us (Heleno et al. 2012), showed higher 
antioxidant properties, measured by the same in vitro assays. 
The effects of GS and GCN on the growth of five human tumour cell lines (MCF-7, 
NCI-H460, HCT-15, HeLa and HepG2) are presented in Table 4. GS revealed activity 
against MCF-7 (GI50 309.66 µg/mL) and HeLa (GI50 311.19 µg/mL) cell lines, while no 
effect was noted in NCI-H460, HCT-15 and HepG2 cell lines at maximum dose of 
400 µg/mL. GCN had no cytotoxic effects towards any of the tested cell lines at the 
maximum concentration used. It should be highlighted that none of the samples showed 
toxicity in a non-tumour liver primary cell culture. 
Despite some reports on antitumour activity of G. lucidum (mainly against breast 
cancer), it should be noticed that the bioactivity was related to polysaccharides (β-1,3-
glucans) and triterpenes (ganoderic acids and others) (Ferreira et al. 2010; Martinez-
Montemayor et al. 2011). In the present study, the bioactivity of extracts rich in 
phenolic compounds and other hydrophilic molecules was assessed, revealing that GS 
had some cytotoxic effect on breast and cervical cell lines.  
Results of antibacterial and antifungal activity towards pathogenic bacteria and fungi, 
evaluated by microdilution method, are presented in the Table 5. Both extracts 
expressed antibacterial activity in a dose dependent mode. The antibacterial effect was 
also dependent on the tested bacteria, but the most sensitive species was B. cereus. 
Otherwise, the most resistant one was E. coli. The antibacterial activity of GS decreased 
in order: B cereus = P. aeruginosa = E. cloacae > S. typhimurium > S. aureus = M. 
flavus = L. monocytogenes > E. coli. Considering GCN, the order was: B cereus > S. 
aureus = P. aeruginosa = S. typhimurium = E. cloacae > M. flavus > L. monocytogenes 
= E. coli. Comparing the results obtained for G. lucidum extracts with commercial 
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antibiotics streptomycin and ampicillin, it is noticeable that both samples exhibited 
stronger antimicrobial potential for most of the tested bacteria. The obtained results 
were better than those published by other authors (MIC and MBC of G. lucidum extract 
at 1 mg/mL) (Sheena et al. 2003; Quereshi et al. 2010).  
Both samples also revealed good antifungal activity. A. versicolor was the most 
susceptible species to GS, while T. viride and P. funiculosum were the most sensitive to 
GCN. A. niger and P. aurantiogriseum were the most resistant fungi species to GS, 
while A. niger was the most resistant to GCN. The antifungal activity of GS decreased 
in order: A. versicolor > A. fumigatus = T. viride > A. ochraceus = P. funiculosum > P. 
ochrochloron > A. niger = P. aurantiogriseum. Antifungal activity of GCN decreased 
in order: T. viride = P. funiculosum > A. ochraceus > A. versicolor = P. ochrochloron 
> P. aurantiogriseum > A. fumigatus > A. niger. Comparing the results of antimycotic 
standards and extracts, it seems clear that in most cases both GS and GCN expressed 
higher antimicrobial potential than ketoconazole and bifonazole. 
Overall, the chemical and bioactive properties of G. lucidum proved to be highly 
dependent on the origin of the samples, i.e. Serbia and China. G. lucidum revealed 
important bioactive molecules such as reducing sugars, organic acids, phenolic 
compounds, unsaturated fatty acids, tocopherols and ergosterol. Furthermore, the 
methanolic extract gave promising antioxidant, cytotoxic (for human tumour cell lines) 
and antimicrobial activities, without hepatotoxicity.  
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Table 1. Nutritional value (mean ± SD; n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In each row different letters mean significant differences (p<0.05). 
 
Ganoderma lucidum  
(Serbia; GS) 
Ganoderma lucidum  
(China; GCN) 
Fat (g/100 g dw) 4.43 ± 0.00a 3.72 ± 0.00b 
Proteins (g/100 g dw) 11.34 ± 1.21a 9.93 ± 0.26b 
Ash (g/100 g dw) 2.80 ± 0.01b 8.19 ± 0.10a 
Carbohydrates (g/100 g dw) 81.48 ± 1.11a 78.16 ± 0.21b 
Energy (Kcal/100 g dw) 410.93 ± 0.04a 385.86 ± 0.29b 
 23 
Table 2. Hydrophilic compounds (mean ± SD; n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Including the related compound cinnamic acid. dw- dry weight; nd- not detected. In each row different 
letters mean significant differences (p<0.05). 
 
Ganoderma lucidum 
 (Serbia; GS) 
Ganoderma lucidum 
(China; GCN) 
Fructose 5.24 ± 0.01 nd 
Glucose 1.18 ± 0.08 nd 
Mannitol 1.60 ± 0.08a 0.45 ± 0.04b 
Sucrose 0.74 ± 0.01 nd 
Trehalose 0.38 ± 0.00a 0.30 ±0.06b 
Total Sugars (g/100 g dw) 9.14 ± 0.14a 0.75 ± 0.03b 
Oxalic acid 0.13 ± 0.00b 1.10 ± 0.03a 
Quinic acid 0.25 ± 0.07b 1.19 ± 0.16a 
Malic acid 0.34 ± 0.07b 2.27 ± 0.06a 
Citric acid 0.61 ± 0.00 nd 
Fumaric acid 0.01 ± 0.00 nd 
Total organic acids (g/100 g dw) 1.34 ± 0.15b 4.57 ± 0.13a 
Protocatechuic acid  0.11 ± 0.00b 2.87± 0.06a 
p-Hydroxybenzoic acid nd 0.31 ± 0.03 
p-Coumaric acid 0.16 ± 0.00 nd 
Cinnamic acid 0.10 ± 0.00a 0.12 ± 0.00a 
Total phenolic compounds* (mg/100 g dw) 0.37 ± 0.00b 3.30 ± 0.03a 
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Table 3. Lipophilic compounds (mean ± SD; n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SFA- Saturated fatty acids; MUFA- Monounsaturated fatty acids; PUFA- Polyunsaturated fatty acids.   
dw- dry weight; nd- not detected. In each row different letters mean significant differences (p<0.05). 
 Ganoderma lucidum 
 (Serbia; GS) 
Ganoderma lucidum 
(China; GCN) 
C16:0 12.01 ± 0.01a 18.54 ± 0.13a 
C18:0 1.33 ± 0.02b 7.34 ± 0.06a 
C18:1n9c 47.24 ± 0.04a 24.06 ± 0.00b 
C18:2n6c 33.94 ± 0.03b 39.80 ± 0.05a 
C18:3n3 0.38 ± 0.00b 2.23 ± 0.24a 
SFA (relative percentage) 15.67 ± 0.03b 32.39 ± 0.17a 
MUFA (relative percentage) 49.63 ± 0.02a 25.19 ± 0.06b 
PUFA (relative percentage) 34.70 ± 0.01b 42.42 ± 0.11a 
α-tocopherol 15.02 ± 0.66 nd 
δ-tocopherol  89.73 ± 7.64  nd 
Total tocopherols (µg/100 g dw) 104.75 ± 8.30 nd 
Ergosterol (mg/100 g dw) 81.56 ± 0.06b  766.18 ± 7.07a 
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Table 4. Antioxidant and cytotoxic activities (mean ± SD; n=3). 
 
 
Ganoderma lucidum  
(Serbia; GS) 
Ganoderma lucidum 
(China; GCN) 
Positive control* 
Antioxidant activity    
DPPH scavenging activity 
(EC50, mg/mL) 
1.71 ± 0.07a 1.33 ± 0.10b 0.04 ± 0.00 
Reducing power  
(EC50, mg/mL) 
0.46 ± 0.01a 0.38 ± 0.00b 0.03 ± 0.00 
β-carotene bleaching inhibition  
(EC50, mg/mL) 
0.31 ± 0.04a 0.22 ± 0.01b 0.003 ± 0.000 
TBARS inhibition  
(EC50, mg/mL)  
0.19 ± 0.06a 0.23 ± 0.07a 0.004 ± 0.000 
Antitumour activity    
MCF-7 (breast carcinoma) 
(GI50, µg/mL) 
309.66±12.95 >400 0.91±0.04 
NCI-H460 (non-small cell lung cancer) 
(GI50, µg/mL) 
>400 >400 1.42±0.00 
HCT-15 (colon carcinoma) 
(GI50, µg/mL) 
>400 >400 1.91±0.06 
HeLa (cervical carcinoma) 
(GI50, µg/mL) 
311.19 ± 6.15 >400 1.14±0.21 
HepG2 (hepatocellular carcinoma) 
(GI50, µg/mL) 
>400 >400 3.22±0.67 
Hepatotoxicity    
PLP2 (GI50, µg/mL) >400 >400 2.06±0.03 
 
*Trolox and ellipticine for antioxidant and cytotoxic activity assays, respectively. EC50 values correspond 
to the sample concentration achieving 50% of antioxidant activity or 0.5 of absorbance in reducing power 
assay. GI50 values correspond to the sample concentration achieving 50% of growth inhibition in human 
tumour cell lines or in liver primary culture PLP2. In each row different letters mean significant 
differences (p<0.05). 
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Table 5. Antibacterial and antifungal activities. 
 
MIC- Minimal inhibitory concentration; MBC- Minimal bactericide concentration; MFC- 
Minimal fungicide concentration.  
Bacteria 
Ganoderma lucidum  
(Serbia; GS) 
MIC/MBC (mg/mL) 
Ganoderma lucidum 
(China; GCN) 
MIC/MBC (mg/mL) 
Streptomycin 
 
MIC/MBC (mg/mL) 
Ampicillin 
 
MIC/MBC (mg/mL) 
Staphylococcus aureus  0.15/0.30 0.07/0.15 0.04/0.09 0.25/0.37 
Bacillus  cereus  0.017/0.035 0.035/0.07 0.09/0.17 0.25/0.37 
Micrococcus  flavus 0.15/0.30 0.10/0.15 0.17/0.34 0.25/0.37 
Listeria monocytogenes  0.15/0.30 0.15/0.30 0.17/0.34 0.37/0.49 
Pseudomonas aeruginosa 0.017/0.035 0.07/0.15 0.17/0.34 0.74/1.24 
Salmonella typhimurium 0.035/0.07 0.07/0.15 0.17/0.34 0.37/0.49 
Escherichia coli    0.30/0.60 0.15/0.30 0.17/0.34 0.25/0.49 
Enterobacter cloacae 0.017/0.07 0.07/0.15 0.26/0.52 0.37/0.74 
Fungi 
Ganoderma lucidum  
(Serbia; GS) 
MIC/MFC (mg/mL) 
Ganoderma lucidum 
(China; GCN) 
MIC/MFC (mg/mL) 
Bifonazole 
 
MIC/MBC (mg/mL) 
Ketoconazole 
 
MIC/MBC (mg/mL) 
Aspergillus fumigatus 0.07/2.50 1.00/1.25 0.15/0.20 0.20/0.50 
Aspergillus versicolor 0.035/0.15 0.15/0.30 0.10/0.20 0.20/0.50 
Aspergillus ochraceus 0.15/0.30 0.10/0.15 0.15/0.20 1.50/2.00 
Aspergillus niger 0.6/2.50 1.50/2.50 0.15/0.20 0.20/0.50 
Trichoderma viride 0.07/0.15 0.07/0.15 0.15/0.20 1.00/1.00 
Penicillium funiculosum  0.15/0.60 0.07/0.15 0.20/0.25 0.20/0.50 
Penicillium ochrochloron 0.30/0.60 0.15/0.30 0.20/0.25 2.50/3.50 
Penicillium aurantiogriseum  0.60/2.50 0.30/0.6 0.10/0.20 0.20/0.30 
